ATYR — aTyr Pharma, Inc.

Is ATYR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

aTyr Pharma, Inc. (ATYR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $5.24. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

aTyr Pharma, Inc. (ATYR) is a clinical-stage biotechnology company whose equity value is tightly linked to pipeline progress and financing outcomes. The company appears vulnerable to dilution risk absent clear near-term positive data or partnering, while sector flows favoring large-cap pharma limit speculative investor appetite. Potential catalyst paths include positive trial readouts, strategic partnerships, or M&A interest; downside scenarios include clinical setbacks, funding challenges, or regulatory delays. With limited social and EDGAR signal coverage, price action will likely remain driven by binary operational updates and broader small-cap biotech funding conditions.

Key factors

  • Clinical-stage, pipeline-driven value profile; near-term movement dependent on trial readouts or partnering announcements
  • Limited/no meaningful commercial revenue; valuation tied to R&D progress and financing visibility
  • Capital markets environment and sector flows favor large-cap pharma, reducing speculative interest in smaller biotech names
  • Potential upside from licensing, partnership or M&A interest given attractive assets for larger pharma
  • Execution risk around clinical development timelines and regulatory milestones
  • Low social/research coverage and limited EDGAR comparables constrain immediate sentiment-driven rallies

Risks

  • Clinical trial failure or disappointing clinical data that could materially reduce valuation
  • Need for additional financing leading to dilution or expensive convertible financings
  • Regulatory delays or negative agency feedback on development programs
  • Competitive risk from larger pharma or alternative therapeutic approaches
  • Low daily liquidity and heightened share-price volatility in a small-cap biotech
  • Macro funding environment tightening, raising cost of capital and pressuring mid/small-cap biotechs

See today's live rating, score and targets

Members see the live hourly rating for ATYR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.